| __timestamp | Bio-Techne Corporation | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 30945000 | 79696000 |
| Thursday, January 1, 2015 | 40853000 | 93236000 |
| Friday, January 1, 2016 | 45187000 | 150842000 |
| Sunday, January 1, 2017 | 53514000 | 150643000 |
| Monday, January 1, 2018 | 55329000 | 150252000 |
| Tuesday, January 1, 2019 | 62413000 | 140804000 |
| Wednesday, January 1, 2020 | 65192000 | 34236000 |
| Friday, January 1, 2021 | 70603000 | 35672000 |
| Saturday, January 1, 2022 | 87140000 | 66607000 |
| Sunday, January 1, 2023 | 92493000 | 76363000 |
| Monday, January 1, 2024 | 96664000 | 79048000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Bio-Techne Corporation and Halozyme Therapeutics, Inc. have demonstrated contrasting R&D strategies. From 2014 to 2023, Bio-Techne's R&D expenses surged by approximately 212%, reflecting a consistent commitment to innovation. In contrast, Halozyme's R&D spending peaked in 2016, with a notable 89% increase from 2014, before experiencing fluctuations and a significant drop in 2020.
Bio-Techne's steady increase in R&D investment highlights its strategic focus on long-term growth, while Halozyme's variable spending suggests a more adaptive approach, possibly influenced by market conditions or project-specific needs. The data for 2024 is incomplete, indicating potential shifts in strategy or reporting. As these companies continue to navigate the competitive biotech landscape, their R&D investments will likely play a pivotal role in shaping their future trajectories.
Analyzing R&D Budgets: Vertex Pharmaceuticals Incorporated vs Bio-Techne Corporation
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Bio-Techne Corporation
Research and Development Investment: BeiGene, Ltd. vs Halozyme Therapeutics, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Bio-Techne Corporation vs Ultragenyx Pharmaceutical Inc.
Research and Development Expenses Breakdown: Bio-Techne Corporation vs Amicus Therapeutics, Inc.
Research and Development Investment: Bio-Techne Corporation vs Mesoblast Limited
Bio-Techne Corporation vs Iovance Biotherapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Bio-Techne Corporation vs BioCryst Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
R&D Insights: How Halozyme Therapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds